10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
17.77
-0.38 (-2.09%)
At close: Dec 5, 2025, 4:00 PM EST
17.80
+0.03 (0.17%)
After-hours: Dec 5, 2025, 6:26 PM EST
10x Genomics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for 10x Genomics stock have an average target of 14.73, with a low estimate of 6.50 and a high estimate of 20. The average target predicts a decrease of -17.11% from the current stock price of 17.77.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 10x Genomics stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 7 | 4 | 5 | 5 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 15 | 11 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $17 → $20 | Buy → Hold | Downgrades | $17 → $20 | +12.55% | Dec 2, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $15 → $19 | Hold | Maintains | $15 → $19 | +6.92% | Nov 11, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $16 → $19 | Strong Buy | Maintains | $16 → $19 | +6.92% | Nov 7, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $13 → $15 | Hold | Maintains | $13 → $15 | -15.59% | Nov 7, 2025 |
| UBS | UBS | Hold Maintains $13 → $14 | Hold | Maintains | $13 → $14 | -21.22% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
638.26M
from 610.79M
Increased by 4.50%
Revenue Next Year
615.90M
from 638.26M
Decreased by -3.50%
EPS This Year
-0.50
from -1.52
EPS Next Year
-0.96
from -0.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 665.7M | 652.4M | ||||
| Avg | 638.3M | 615.9M | ||||
| Low | 606.6M | 584.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 9.0% | 2.2% | ||||
| Avg | 4.5% | -3.5% | ||||
| Low | -0.7% | -8.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.42 | -0.56 | ||||
| Avg | -0.50 | -0.96 | ||||
| Low | -0.99 | -1.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.